{"filing":{"accession_number":"0001448431-26-000014","cik":"0001448431","ticker":"OPRX","company_name":"OptimizeRx Corp","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-07","primary_document":"oprx-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1448431/000144843126000014/oprx-20260807.htm"},"events":[{"id":27179,"run_id":24753,"accession_number":"0001448431-26-000014","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"OptimizeRx issued a press release on August 12, 2026 announcing Q2 2026 financial results, including revenue of $20.5 million, net loss of $(0.7) million, and adjusted EBITDA of $4.9 million, along with reaffirmed full-year 2026 guidance.","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28600,"accession_number":"0001448431-26-000014","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"OptimizeRx issued a press release on August 12, 2026 announcing Q2 2026 financial results, including revenue of $20.5 million, net loss of $(0.7) million, and adjusted EBITDA of $4.9 million, along with reaffirmed full-year 2026 guidance. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial statements and KPIs material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":27180,"run_id":24753,"accession_number":"0001448431-26-000014","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.7,"summary":"Edward Stelmakh departed as Chief Financial \u0026 Strategy Officer effective December 31, 2026, with a separation agreement providing $450K salary continuation, $247.5K bonus, COBRA, and advisory services through 2027. Concurrent appointments of D'Silva as CFO and Favazza as Chief Accounting Officer effective January 1, 2027 establish a succession plan.","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28601,"accession_number":"0001448431-26-000014","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"Edward Stelmakh's departure as Chief Financial \u0026 Strategy Officer effective December 31, 2026 is the primary disclosed action, though the filing also covers two concurrent appointments (D'Silva and Favazza). The separation agreement with severance terms ($450K salary continuation, $247.5K bonus, COBRA, and advisory services through 2027) is material to investors assessing leadership continuity and financial obligations. While this is a succession plan with replacements identified, the salient event is Stelmakh's departure from a named executive officer role.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28602,"accession_number":"0001448431-26-000014","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 7.01 disclosure announces the departure of Mr. Stelmakh as Chief Financial \u0026 Strategy Officer, effective December 31, 2026, alongside appointments of two new executives (D'Silva as CFO and Favazza as Chief Accounting Officer) effective January 1, 2027. While both a departure and appointments occur, the prose centers on Stelmakh's stepping down from a C-suite financial leadership role, making exec_departure the primary event. The departure of a CFO is material to investors assessing management continuity and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28600,"accession_number":"0001448431-26-000014","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"OptimizeRx issued a press release on August 12, 2026 announcing Q2 2026 financial results, including revenue of $20.5 million, net loss of $(0.7) million, and adjusted EBITDA of $4.9 million, along with reaffirmed full-year 2026 guidance. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial statements and KPIs material to investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-08-12"},{"id":28601,"accession_number":"0001448431-26-000014","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.65,"reasoning":"Edward Stelmakh's departure as Chief Financial \u0026 Strategy Officer effective December 31, 2026 is the primary disclosed action, though the filing also covers two concurrent appointments (D'Silva and Favazza). The separation agreement with severance terms ($450K salary continuation, $247.5K bonus, COBRA, and advisory services through 2027) is material to investors assessing leadership continuity and financial obligations. While this is a succession plan with replacements identified, the salient event is Stelmakh's departure from a named executive officer role.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-08-12"},{"id":28602,"accession_number":"0001448431-26-000014","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Item 7.01 disclosure announces the departure of Mr. Stelmakh as Chief Financial \u0026 Strategy Officer, effective December 31, 2026, alongside appointments of two new executives (D'Silva as CFO and Favazza as Chief Accounting Officer) effective January 1, 2027. While both a departure and appointments occur, the prose centers on Stelmakh's stepping down from a C-suite financial leadership role, making exec_departure the primary event. The departure of a CFO is material to investors assessing management continuity and financial oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:28.513987+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-08-12"}]}